Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Pediatricians in Private Practice (US)

Articles with lock require a subscription to GLG News | Request a free trial
October 13, 2008
When Your Neighbor Takes an Antibiotic, So Do You
Analysis of: C. Difficile And Antibiotics Not Necessarily Linked, Study Finds | www.sciencedaily.com
Author: GLG Expert Contributor
This study did not conclude that antibiotic use does not precipitate C. difficile infections.  What it found was that the individuals who are infected with C. diff did not necessarily take antibiotics in the six weeks preceding their infection.  In my mind, rather than demonstrating that C....
October 6, 2008
cold medications overdose- med fault or Dr. fault?
Analysis of: FDA urged to recall cold medicines for youngsters | news.yahoo.com
Author: GLG Expert Contributor
There is a alot of information in the media  about the dangers of givng OTC cough medication to young children . Many children have ended up in the emergency room after "over-ingesting" "cold remedy products that include OTC antihistamines, decongestants and  cough suppressants. Also when...
September 29, 2008
Published Evidence Bias: Approved Drugs Are Just the Tip of the Iceberg
Analysis of: Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
Author: GLG Expert Contributor
This study looked at drugs that were eventually approved by the FDA, and found that only 43% of early phase (non-"pivotal") trials were published in the medical literature.  But imagine what this means for drugs that ultimately fail: if drugs that are destined for success are withholding 57% of...
August 6, 2008
At What Cost Prevention?
Analysis of: Researchers Look to Pill, Taken Daily, to Avert H.I.V. | www.nytimes.com
Author: GLG Expert Contributor
There is already a bounty of data to support anti-retroviral (and other) HIV medications in post-exposure prophylaxis, be it in infants born to HIV-positive mothers; intra-partum prophylaxis to HIV-positive women in active labor; and to healthcare workers (and others) exposed to HIV from accidental...
June 10, 2008
Will Xolair Become Obsolete in the Treatment of Allergies?
Analysis of: Investigational Anti-IgE Antibody Promising as Extracorporeal Allergy Therapy | www.medscape.com
Author: Mark Vandewalker, Allergy Specialist and Partner, Allergy & Asthma Consultants Of The Ozarks Ltd
This recent report characterizes a newly discovered anti-IgE monoclonal antibody (mAb12) which appears dramatically more potent than omalizumab (Xolair) in its ability to reduce systemic IgE levels. If further studies confirm this enhanced reduction of IgE and IgE-bearing cells, mAb12 has significant...
June 2, 2008
No One is Paying $30K For One More Month
Analysis of: Erbitux Slightly Boosts Survival in Cancer Study | online.wsj.com
Author: GLG Expert Contributor
Or whatever the total cost of Erbitux is that is required to get you four more weeks of life.  This is basically what it comes down to.  Most cost-benefit analyses will justify up to $60K spent per year of life in amortized costs, but not above that.  So the total costs of Erbitux...
May 12, 2008
Will Strattera be around in 3 years?
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
Author: GLG Expert Contributor
My personal prediction is that this product will NOT be on the market in 3-5 years.  My clinical experience never approached that which the research would suggest.  I suspect that the "research" that was done on this product is frought with company incentives.
May 12, 2008
does straterra work?
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
Author: GLG Expert Contributor
we really have had little luck with straterra in  our office.  Even at high  doses,  the drug rarely does the trick
May 12, 2008
merck does the work
Analysis of: FDA Approves ROTARIX(R) Rotavirus Vaccine | www.pipelinereview.com
Author: GLG Expert Contributor
the vaccines may be similar, but I'll stick with the Merck product
May 12, 2008
bubbles always BURST
Analysis of: Speculators knock OPEC off oil-price perch | www.atimes.com
Author: GLG Expert Contributor
what goes up must come down.  This speculation in oil has happened many times during my lifetime and it is the same with all commodites (remember the holland tulips).  Yes, many have and will make fortunes in commoditiy trades, but in the end the real intrinsic value comes through.  When...

Page : 1 2 3 4 5 6 7 Next1 to 10 of 62

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203